Takeda has been selected for the seventh consecutive year for Dow Jones Sustainability Asia Pacific Index

Takeda has been selected for the seventh consecutive year for Dow Jones Sustainability Asia Pacific Index

September 21, 2016

Osaka, Japan, September 21, 2016 --- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that for the seventh consecutive year it has been selected for the Dow Jones Sustainability Asia Pacific Index ("DJSI Asia Pacific"), which is one of the world foremost indices for Socially Responsible Investment (SRI)*. In this year, Takeda received particularly high marks in the Environment category.

DJSI Asia Pacific is part of the Dow Jones Sustainability Indexes (DJSI), which is provided by S&P Dow Jones Indices LLC of the United States. It is designed for companies in the developed Asia Pacific markets and comprises 146 companies this year, including 68 Japanese companies that are leading the way in terms of sustainability among the 600 companies in the region. For inclusion in the DJSI Asia Pacific, Dow Jones assesses companies based on questionnaire responses, annual reports from each company and publicly available company information. It assesses and selects leading sustainability-driven companies based on economic, environmental, and social criteria. Thus it serves as an important indicator for investors considering corporate social responsibility (CSR) performance.

Takeda is also included in the FTSE4Good Global Index by the FTSE Group of the United Kingdom for twelfth consecutive year and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K for eighth consecutive year.

For Takeda, CSR is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. The company also strives to maintain and improve sound business processes, and to engage in activities to promote a sustainable society as a good corporate citizen. In doing so, it is implementing a model of value creation and preservation through CSR. This will help Takeda to build trust with society, reinforce its reputation, and further develop the pharmaceutical business.

* SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news/.